XL092 (Synonyms: XL092) |
| Catalog No.GC62266 |
XL092 es un inhibidor competitivo de ATP activo por vÍa oral de mÚltiples tirosina quinasas receptoras (RTK), incluidos MET, VEGFR2, AXL y MER, con IC50 en ensayos basados en células de 15 nM, 1,6 nM, 3,4 nM, 7,2 nM respectivamente. XL092 exhibe actividad antitumoral. XL092 tiene el potencial para la investigaciÓn de enfermedades y condiciones dependientes de quinasa.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2367004-54-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
XL092 is a potent inhibitor of the activity of Axl, Mer and C-Met kinase with IC50s of <10 nM, respectively. XL092 exhibits anti-tumor activity and has the potential for kinase-dependent diseases and conditions research[1].
XL092 (compound 8; 3 mg/kg; iv) has a T1/2 of 5.4 hours, a CL of 43 mL/hr•kg. XL092 (3 mg/kg; po) has a T1/2 of 7.1 hours and a Cmax of 11.4 μM for rats[1].
[1]. Lynne Canne Bannen, et al. Compounds for the treatment of kinase-dependent disorders. WO2019148044A1.
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *